Brent Tan, MD
Pathology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
- Since medical school
- 25 years
- University of California, Geffen School of Medicine, 2001
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Tan’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A86418 · Current
Licensed to practise in California · since 2004 · expires 2027-11-30 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$51,416
Medicare paid this office $51,416 for 345 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 147 | $11,339 | $72 |
| Special stained specimen slides to examine tissue, each additional procedure | 58 | $6,969 | $25 |
| Pathology examination of tissue using a microscope, intermediate complexity | 114 | $6,324 | $33 |
| Bone marrow, smear interpretation | 113 | $5,186 | $43 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 69 | $5,035 | $71 |
See all 15 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 147 | $11,339 | $72 |
| Special stained specimen slides to examine tissue, each additional procedure | 58 | $6,969 | $25 |
| Pathology examination of tissue using a microscope, intermediate complexity | 114 | $6,324 | $33 |
| Bone marrow, smear interpretation | 113 | $5,186 | $43 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 69 | $5,035 | $71 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 59 | $3,337 | $54 |
| Special stained specimen slides to examine tissue, initial procedure | 69 | $2,262 | $31 |
| Microscopic genetic analysis of tumor, manual | 37 | $1,903 | $37 |
| Genetic sequencing localization, initial procedure | 43 | $1,654 | $38 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 20 | $1,590 | $79 |
| Preparation of tissue for examination by removing any calcium present | 107 | $1,257 | $11 |
| Special stained specimen slides to examine tissue including interpretation and report | 69 | $849 | $11 |
| Genetic sequencing localization, each additional procedure | 24 | $848 | $30 |
| Cell examination of specimen, concentration technique | 32 | $689 | $20 |
| Blood smear interpretation by physician with written report | 14 | $301 | $22 |
Who their Medicare patients are
345 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 12% · Women 47% · Also on Medicaid 23% · Health risk score 2.21. Above the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 75% · Chronic kidney disease 34% · Diabetes 30% · Coronary heart disease 30% · Atrial fibrillation 26% · Depression 23% · Heart failure 22% · Cancer 20% · COPD 16% · Dementia 12% · Stroke 12%.
The office billed $532,949, Medicare allowed $65,910 and paid $51,416; for 1,380 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 345 | 1,380 | 74 | 2.21 | $532,949 | $51,416 |
| 2023 | 316 | 957 | 73 | 1.85 | $328,075 | $40,756 |
| 2022 | 290 | 1,001 | 74 | 1.98 | $292,754 | $39,360 |
| 2021 | 305 | 1,569 | 73 | 1.93 | $402,231 | $59,170 |
| 2020 | 292 | 1,462 | 72 | 2.21 | $365,619 | $55,524 |
| 2019 | 296 | 1,181 | 72 | 2.39 | $293,181 | $45,814 |
| 2018 | 73 | 203 | 70 | 2.54 | $51,793 | $9,000 |
| 2017 | 231 | 1,170 | 72 | 2.30 | $286,710 | $46,158 |
| 2016 | 322 | 1,396 | 71 | 1.86 | $339,627 | $57,160 |
| 2015 | 274 | 1,297 | 72 | 1.94 | $297,557 | $48,011 |
| 2014 | 267 | 1,003 | 71 | 2.15 | $256,350 | $38,065 |
| 2013 | 193 | 630 | 72 | 1.95 | $164,720 | $28,174 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 125 | $9,721 | $76 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 79 | $5,757 | $73 |
| Special stained specimen slides to examine tissue, each additional procedure | 41 | $5,354 | $26 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 59 | $4,114 | $58 |
| Pathology examination of tissue using a microscope, intermediate complexity | 69 | $3,446 | $34 |
| Bone marrow, smear interpretation | 64 | $2,969 | $44 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 23 | $1,876 | $82 |
| Special stained specimen slides to examine tissue, initial procedure | 53 | $1,755 | $32 |
| Microscopic genetic analysis of tumor, manual | 25 | $1,594 | $39 |
| Genetic sequencing localization, initial procedure | 25 | $1,005 | $40 |
| Preparation of tissue for examination by removing any calcium present | 64 | $782 | $11 |
| Genetic sequencing localization, each additional procedure | 14 | $508 | $32 |
| Special stained specimen slides to examine tissue including interpretation and report | 32 | $422 | $11 |
| Cell examination of specimen, concentration technique | 18 | $397 | $21 |
2022: 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 103 | $8,199 | $77 |
| Special stained specimen slides to examine tissue, each additional procedure | 52 | $6,678 | $26 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 57 | $4,144 | $73 |
| Bone marrow, smear interpretation | 71 | $3,256 | $44 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 41 | $2,781 | $58 |
| Pathology examination of tissue using a microscope, intermediate complexity | 74 | $2,766 | $35 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 32 | $2,592 | $81 |
| Special stained specimen slides to examine tissue, initial procedure | 63 | $2,076 | $32 |
| Genetic sequencing localization, initial procedure | 34 | $1,383 | $41 |
| Microscopic genetic analysis of tumor, manual | 24 | $1,164 | $39 |
| Cell examination of specimen, concentration technique | 41 | $907 | $21 |
| Preparation of tissue for examination by removing any calcium present | 70 | $845 | $12 |
| Genetic sequencing localization, each additional procedure | 22 | $800 | $32 |
| Special stained specimen slides to examine tissue including interpretation and report | 40 | $526 | $11 |
2021: 16 services
| Special stained specimen slides to examine tissue, each additional procedure | 90 | $15,956 | $27 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 98 | $7,796 | $78 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 61 | $5,202 | $83 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 59 | $4,749 | $79 |
| Microscopic genetic analysis of tumor, manual | 59 | $4,366 | $40 |
| Special stained specimen slides to examine tissue, initial procedure | 99 | $3,547 | $33 |
| Bone marrow, smear interpretation | 75 | $3,396 | $44 |
| Pathology examination of tissue using a microscope, intermediate complexity | 80 | $3,043 | $35 |
| Genetic sequencing localization, initial procedure | 56 | $2,448 | $41 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 28 | $1,775 | $57 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 16 | $1,568 | $60 |
| Genetic sequencing localization, each additional procedure | 32 | $1,356 | $33 |
| Preparation of tissue for examination by removing any calcium present | 77 | $922 | $12 |
| Cell examination of specimen, concentration technique | 38 | $797 | $20 |
| Special stained specimen slides to examine tissue including interpretation and report | 44 | $643 | $11 |
| Blood smear interpretation by physician with written report | 16 | $367 | $23 |
2020: 16 services
| Special stained specimen slides to examine tissue, each additional procedure | 92 | $14,428 | $28 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 78 | $5,966 | $76 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 63 | $5,336 | $83 |
| Microscopic genetic analysis of tumor, manual | 57 | $4,366 | $41 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 52 | $4,059 | $78 |
| Special stained specimen slides to examine tissue, initial procedure | 99 | $3,699 | $35 |
| Bone marrow, smear interpretation | 74 | $3,437 | $46 |
| Pathology examination of tissue using a microscope, intermediate complexity | 81 | $3,273 | $36 |
| Genetic sequencing localization, initial procedure | 54 | $2,433 | $43 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 26 | $1,670 | $58 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 18 | $1,616 | $62 |
| Genetic sequencing localization, each additional procedure | 23 | $1,147 | $34 |
| Preparation of tissue for examination by removing any calcium present | 72 | $884 | $12 |
| Cell examination of specimen, concentration technique | 38 | $859 | $21 |
| Special stained specimen slides to examine tissue including interpretation and report | 42 | $738 | $12 |
| Blood smear interpretation by physician with written report | 12 | $258 | $21 |
2019: 16 services
| Special stained specimen slides to examine tissue, each additional procedure | 59 | $9,215 | $28 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 81 | $6,614 | $80 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 75 | $5,693 | $76 |
| Pathology examination of tissue using a microscope, intermediate complexity | 75 | $3,098 | $36 |
| Bone marrow, smear interpretation | 66 | $3,064 | $46 |
| Special stained specimen slides to examine tissue, initial procedure | 67 | $2,652 | $34 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 31 | $2,578 | $83 |
| Microscopic genetic analysis of tumor, manual | 33 | $2,517 | $41 |
| Genetic sequencing localization, initial procedure | 39 | $1,718 | $42 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 24 | $1,501 | $58 |
| Cell examination of specimen, concentration technique | 50 | $1,109 | $20 |
| Genetic sequencing localization, each additional procedure | 20 | $1,030 | $33 |
| Preparation of tissue for examination by removing any calcium present | 67 | $820 | $12 |
| Special stained specimen slides to examine tissue including interpretation and report | 47 | $782 | $11 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 16 | $566 | $35 |
| Blood smear interpretation by physician with written report | 12 | $284 | $22 |
2018: 4 services
| Surgical pathology consultation and report on referred slides prepared elsewhere | 26 | $1,975 | $76 |
| Special stained specimen slides to examine tissue, each additional procedure | 13 | $1,603 | $27 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 14 | $1,109 | $79 |
| Special stained specimen slides to examine tissue, initial procedure | 16 | $542 | $34 |
2017: 14 services
| Special stained specimen slides to examine tissue, each additional procedure | 68 | $8,052 | $27 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 74 | $6,245 | $83 |
| Bone marrow, smear interpretation | 82 | $4,095 | $46 |
| Pathology examination of tissue using a microscope, intermediate complexity | 93 | $3,823 | $36 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 44 | $3,591 | $82 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 47 | $3,515 | $75 |
| Microscopic genetic analysis of tumor, manual | 40 | $3,281 | $52 |
| Special stained specimen slides to examine tissue, initial procedure | 81 | $3,108 | $34 |
| Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | 12 | $2,091 | $60 |
| Genetic sequencing localization, initial procedure | 42 | $1,845 | $42 |
| Preparation of tissue for examination by removing any calcium present | 80 | $1,045 | $12 |
| Cell examination of specimen, concentration technique | 31 | $840 | $22 |
| Special stained specimen slides to examine tissue including interpretation and report | 48 | $810 | $11 |
| Genetic sequencing localization, each additional procedure | 18 | $793 | $33 |
2016: 17 services
| Special stained specimen slides to examine tissue, each additional procedure | 93 | $11,420 | $25 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 85 | $8,772 | $101 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 85 | $6,689 | $78 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 65 | $5,255 | $80 |
| Bone marrow, smear interpretation | 77 | $3,866 | $45 |
| Special stained specimen slides to examine tissue, initial procedure | 102 | $3,573 | $34 |
| Pathology examination of tissue using a microscope, intermediate complexity | 81 | $3,528 | $36 |
| Microscopic genetic analysis of tumor, manual | 44 | $3,022 | $51 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 22 | $2,175 | $84 |
| Genetic sequencing localization, initial procedure | 43 | $1,784 | $41 |
| Cell examination of specimen, concentration technique | 34 | $946 | $20 |
| Preparation of tissue for examination by removing any calcium present | 71 | $935 | $12 |
| Microscopic genetic analysis of tissue, manual, each additional procedure | 13 | $713 | $29 |
| Microscopic genetic analysis of tissue, manual, initial procedure | 15 | $552 | $37 |
| Blood smear interpretation by physician with written report | 20 | $507 | $23 |
| Genetic sequencing localization, each additional procedure | 13 | $506 | $32 |
| Special stained specimen slides to examine tissue including interpretation and report | 32 | $494 | $11 |
2015: 17 services
| Special stained specimen slides to examine tissue, each additional procedure | 75 | $8,542 | $20 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 72 | $7,636 | $100 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 60 | $4,606 | $76 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 57 | $4,606 | $81 |
| Pathology examination of tissue using a microscope, intermediate complexity | 81 | $3,368 | $35 |
| Bone marrow, smear interpretation | 67 | $3,113 | $44 |
| Special stained specimen slides to examine tissue, initial procedure | 83 | $2,947 | $33 |
| Genetic sequencing localization, initial procedure | 48 | $2,269 | $41 |
| Microscopic genetic analysis of tumor, manual | 35 | $2,217 | $50 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 21 | $1,981 | $83 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 18 | $1,169 | $65 |
| Preparation of tissue for examination by removing any calcium present | 69 | $832 | $12 |
| Cell examination of specimen, concentration technique | 30 | $645 | $22 |
| Microscopic genetic analysis of tissue, manual, initial procedure | 16 | $635 | $40 |
| Genetic sequencing localization, each additional procedure | 18 | $586 | $24 |
| Special stained specimen slides to examine tissue including interpretation and report | 34 | $585 | $11 |
| Blood smear interpretation by physician with written report | 19 | $431 | $23 |
2014: 15 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 84 | $8,268 | $95 |
| Bone marrow, smear interpretation | 100 | $4,646 | $43 |
| Pathology examination of tissue using a microscope, intermediate complexity | 99 | $3,775 | $35 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 42 | $3,489 | $74 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 30 | $2,335 | $78 |
| Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) | 44 | $1,914 | $11 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 24 | $1,818 | $76 |
| Microscopic genetic analysis of tumor, manual | 29 | $1,770 | $48 |
| Genetic sequencing localization, initial procedure | 20 | $1,571 | $52 |
| Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 53 | $1,461 | $28 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 20 | $1,270 | $64 |
| Preparation of tissue for examination by removing any calcium present | 93 | $1,109 | $11 |
| Special stained specimen slides to examine tissue including interpretation and report | 41 | $801 | $11 |
| Cell examination of specimen, concentration technique | 36 | $744 | $19 |
| Blood smear interpretation by physician with written report | 24 | $519 | $22 |
2013: 14 services
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 76 | $7,553 | $93 |
| Special stained specimen slides to examine tissue, initial procedure | 32 | $4,407 | $38 |
| Bone marrow, smear interpretation | 62 | $2,668 | $42 |
| Pathology examination of tissue using a microscope, intermediate complexity | 63 | $2,217 | $33 |
| Flow cytometry technique for dna or cell analysis, 9 to 15 markers | 17 | $1,484 | $78 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 19 | $1,478 | $74 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 19 | $1,396 | $73 |
| Genetic sequencing localization, initial procedure | 19 | $1,123 | $49 |
| Microscopic genetic analysis of tumor, manual | 19 | $979 | $47 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 14 | $853 | $61 |
| Preparation of tissue for examination by removing any calcium present | 60 | $701 | $11 |
| Cell examination of specimen, concentration technique | 33 | $697 | $20 |
| Blood smear interpretation by physician with written report | 19 | $410 | $22 |
| Special stained specimen slides to examine tissue including interpretation and report | 18 | $297 | $11 |
Medicaid work
$5,393 in 2024
Medicaid paid $5,393 for 182 billed services this clinician did in 2024, up to 31 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 62 | $1,743 |
| Bone marrow, smear interpretation | 27 | $1,417 |
| Blood smear, peripheral, interpretation by physician with written report | 68 | $1,123 |
| Flow cytometry, interpretation; 16 or more markers | 12 | $575 |
| Flow cytometry, interpretation; 9 to 15 markers | 13 | $534 |
| 2024 | 182 | 5 | 31 | $5,393 |
| 2023 | 163 | 7 | 18 | $4,852 |
| 2022 | 209 | 6 | 27 | $5,801 |
| 2021 | 101 | 3 | 22 | $2,324 |
| 2020 | 35 | 1 | 15 | $873 |
| 2019 | 155 | 3 | 27 | $4,404 |
| 2018 | 16 | 1 | 16 | $408 |
See the largest Medicaid services in earlier years
2023
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 43 | $1,159 |
| Bone marrow, smear interpretation | 17 | $879 |
| Flow cytometry, interpretation; 9 to 15 markers | 15 | $756 |
| TISSUE EXAM BY PATHOLOGIST | 12 | $721 |
| Blood smear, peripheral, interpretation by physician with written report | 52 | $717 |
| Consultation and report on referred slides prepared elsewhere | 12 | $532 |
| DECALCIFICATION PROCEDURE | 12 | $88 |
2022
| Flow cytometry, interpretation; 16 or more markers | 25 | $1,809 |
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 70 | $1,341 |
| Bone marrow, smear interpretation | 28 | $1,077 |
| TISSUE EXAM BY PATHOLOGIST | 25 | $963 |
| Blood smear, peripheral, interpretation by physician with written report | 36 | $426 |
| DECALCIFICATION PROCEDURE | 25 | $185 |
2021
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 76 | $1,662 |
| Bone marrow, smear interpretation | 13 | $500 |
| Blood smear, peripheral, interpretation by physician with written report | 12 | $162 |
2020
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 35 | $873 |
2019
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 116 | $3,048 |
| Bone marrow, smear interpretation | 22 | $1,095 |
| Blood smear, peripheral, interpretation by physician with written report | 17 | $260 |
2018
| Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique) | 16 | $408 |
Money from drug and device companies
$21 in 2023
| 2023 | 1 | 1 | None | $21 |
| 2021 | 2 | 2 | $267 | $299 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Hologic Sales and Service | Panther Fusion | $21 | 1 payment
|
See the published payment
| Hologic Sales and Service | Meals · 2023-03-17 | Panther Fusion | $21 |
See earlier years (2021)
2021: $299
| Cepheid | None | $267 | 1 payment
|
| Blueprint Medicines | None | $32 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1134271232
- Licence
- CA A86418California A86418: Current · expires 2027-11-30
- Trained
- University of California, Geffen School of Medicine, 2001 · 25 years ago
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A864180
- Taxonomy
- Federal specialty code 207ZP0101X (207ZP0101X); Federal specialty code 207ZC0008X (207ZC0008X); Federal specialty code 207ZH0000X (207ZH0000X); Federal specialty code 207ZP0102X (207ZP0102X)
- Mailing address
- 300 Pasteur Dr Dept of, Stanford, CA, 94305
- NPI first listed
- 2007-01-17
- NPI last updated
- 2024-03-13
- NPI record certified
- 2024-03-13
This is when the NPI record was last certified, not a medical board exam.